Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK Seeks Marketing Partner (India)

This article was originally published in PharmAsia News

Executive Summary

As part of its attempt to enhance its therapeutic coverage in cardiovascular, diabetes and other high-growth segments, the Indian division of GlaxoSmithKline is searching for brand in-licensing opportunities to market products for lifestyle-related diseases. GlaxoSmithKline Pharmaceuticals Managing Director Hasit B. Joshipura has confirmed that the company is hunting "for partners and we are in discussions with a couple of companies." The announcement marks a departure for GSK's portfolio, which has consisted mainly of traditional therapeutic segments. The redirection will include rolling out products from GSK's portfolio, Joshipura added. (Click here for more

You may also be interested in...



ECHA's ‘Devastating Blow’ To Animal Testing Ban Slammed By Cosmetic Industry, Stakeholders

In an open letter to the European Commission, Parliament and Council presidents, more than 400 cosmetics companies and animal-rights groups accuse the European Chemicals Agency of effectively “shredding” the animal testing ban on cosmetics by requiring testing for certain chemicals under REACH.

Pink Sheet Podcast: UK Clears COVID-19 Vaccine, FDA Pressure Increases; Biden’s FDA Commissioner

Pink Sheet reporters and editors look at the UK MHRA’s surprising approval of the Pfizer/BioNTech coronavirus vaccine, as well as the US reaction, and discuss President-elect Joe Biden’s potential US FDA commissioner nominees.

LivaNova Sells Surgical Heart Valve Business To Gyrus Capital For $73M

Divesting the heart valve division will allow LivaNova to focus more resources on its neuromodulation, cardiopulmonary and circulatory support businesses.

UsernamePublicRestriction

Register

LL1134940

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel